Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead Sciences 2Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Gilead Sciences 2Q11

Revenues hit record, driven by Atripla, Truvada

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences 2Q11

2Q Revenues: $2.1 billion (+11%)

2Q Earnings: $746.2 million (+5%)

YTD Revenues: $4.1 billion (+1%)

YTD Earnings: $1.4 billion (-11%)

Comments: Antiviral product sales were up 11% to $1.8 billion in the quarter. Sales of Atripla increased 15% to $822.0 million, sales of Truvada were up 11% to $711.3 million, and sales of Viread increased 5% to $185.7 million. Sales of Letairis were up 22% to $73.6 million. Sales of Ranexa were up 42% to $86.1 million. Royalty, contract and other revenues were $97.7 million in the quarter, down 19% due to lower Tamiflu royalties from Roche.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters